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Deoxythymidine kinase (TK) catalyzes the
phosphorylation of deoxythymidine to
deoxythymidine monophosphate, an essential
precursor of DNA thymine. Among the different
isoenzymes of TK (ATP: thymidine 5'-
phosphotransferase (EC 2.7.1.21)) present in human
cells, TK1, the cytosolar form of TK, occurs in
large amounts in dividing cells and is more or less
absent from resting differentiated cells (Bello et al.,
1974).
The development of a TK assay optimized for
TK1, utilizing [1251] iododeoxyuridine as substrate,
has been found to facilitate the detection of normal
serum TK (S-TK) levels (Gronowitz et al., 1984).
Elevated S-TK levels were observed in patients with
different malignant diseases, such as chronic
granulocytic leukaemia, acute myeloblastic
leukemia (AML), acute lymphoblastic leukaemia
(ALL), lung cancer of the small cell type, and non-
Hodgkin's lymphoma. The pretreatment S-TK level
in patients with non-Hodgkin's lymphoma
correlated both to clinical stage and to grade of
malignancy. Higher values were consistently found
in patients with advanced disease and histology
(Gronowitz et al., 1983b).
The aim of the present study was to investigate
how the pretreatment level of S-TK correlated to
the type of acute leukaemia, the remission rate and
the duration of remission.
A total of 79 consecutive patients were diagnosed
as having acute leukemia between January 1979
and September 1983 at the University Hospital,
Uppsala. Pretreatment sera were available in 66
patients who are included in this study. Fifty-four
patients were found to have AML and 12 to have
ALL. No patient had suffered from any blood
disorder previously. The mean age of the AML
patients was 46 years (range 19-84) and the male
female ratio was 34:21. The mean age of the ALL
patients was 36 years (range 14-59); seven were
males and five were females. Sera were stored at
-20° until analyzed.
Morphological classification of the AML patients
was performed according to a modification of the
French-American-British (FAB) system (Bennet et
al., 1976) as used by the Leukaemia Group of
Central Sweden. The FAB classification was
modified by defining the percentage of
promyelocytes plus promonocytes to 5% as the
border between MI and M2 respectively M5a and
M5b. Nine of the AML patients were subtyped as
M1, 19 as M2, 8 as M4 and 3 as M5b. The ALL
patients were not subtyped. The percentage of
leukaemic bone marrow infiltration (LBI) was
calculated as the product between estimated
marrow cellularity and percentage of leukaemic
cells according to the formula:
bone marrow cellularity %
x percentage of leukaemic cells
100
All patients with AML, except two men (75 and 84
years old), were given combined chemotherapy.
Twenty-six patients received daunorubicin
1.5mgkg-1 i.v on Day 1 and cytarabine
1 mgkg1 x 2 i.v Days 1-5. The remaining 26
patients were treated more aggressively with
prednisone 30mgm-2 x2 p.o Days 1-7, vincristine
2mg x 1 i.v Days 1 and 5, cytarabine lOOmgm2 i.v
Days 1-7 (infusion over 16h), doxorubicin
30mgm2 i.v Days 4 and 5 and 6-thioguanine
50mgm-2 x 2 p.o Days 1-7. The regimens was
repeated with the shortest possible interval until
complete remission was achieved. The ALL patients
were treated with a combination of vincristine,
doxorubicine, cyclophosphamide, prednisone and
L-asparaginase together with central nervous
system prophylaxis. Complete remission was
defined as normal blood counts and less than 5%
blast cells in bone marrow smears and no blast cell
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aggregates in the bone marrow sections. Criteria for
complete remission also included a response
duration ofmore than one month.
Maintenance therapy was started when the
patients had attained complete remission. The
AML patients received treatment every month for
36 months consisting of cytarabine 1 mgkg-1 x 1 i.v
Days 1-5 together with either 6-thioguanine
1 mgm-2 p.o x 2 Days 1-5 or daunorubicin
1.5mgkg-1 x 1 i.v Day 1, the latter two drugs given
alternately. Patients who had received doxorubicin
during induction of remission were also given
doxorubicin 50mgm-2 instead of daunorobicin
during maintenance therapy. Daunorubicin or
doxorubicin was withdrawn after one year of
maintenance and replaced by 6-thioguanine. Twelve
patients received more extensive maintenance
therapy which also included azacytidine. Patients
with partial remission, progressive disease or
relapse were treated individually. Two patients with
AML underwent a bone marrow transplantation
while in complete remission. Both died shortly after
the transplantation, one of graft-versus-host disease
and the other of cytomegalovirus infection. One
patient with AML in complete remission died of
sepsis during maintenance therapy. The duration of
remission was measured from the date of
achievement of complete remission to the date of
relapse or of the last follow-up, i.e. October 1983.
The enzyme assay system utilized 125I-IUdR
(10-7M, 130-16OCimmol-1), as substrate and has
been described in detail elsewhere (Gronowitz et al.
1984). Under the conditions used, 1 unit of
enzyme is equal to an anzyme activity of
1.2x 10-8 katal, and gives - I000cpm with the
amount of isotope used. The average S-TK level in
healthy subjects is estimated to be 2.4unitspM 1,
with an upper limit of 5.0unitspl-1.
The data were analyzed by linear regression (r)
and the Mann-Whitney test. All P values reported
refer to two-sided tests. The variables S-TK, serum
lactic dehydrogenase and the peripheral blast count
were transformed into logarithmic scale before
linear regression analysis. Remission duration was
analyzed using the Cox's regression model (Cox,
1972).
The pretreatment values for S-TK are plotted in
Figure 1. S-TK was increased (>5.0units) before
treatment in all but three cases. A significant
correlation was found between S-TK and both
peripheral blast cell count (r=0.61; P<0.0001) and
the degree of leukaemic bone marrow infiltration
(r=0.40; P<0.01). There was also a significant
correlation between S-TK and serum lactic
dehydrogenase (r=0.67; P<0.0001). The median S-
TK value for the 54 patients with AML was
84units 1l- and for the patients with ALL
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Figure 1 Pretreatment S-TK levels in 12 patients
with ALL and 54 patients with AML and the response
to treatment. O=complete remission. *b=failure to
achieve complete remission. OJ =nonevaluable with
respect to treatment response.
232unitsp1l-1. These two groups did not differ
significantly with respect to S-TK (P=0.2). No
significant difference in S-TK was found between
the FAB subgroups of AML patients. Besides
giving the pretreatment S-TK values, Figure 1 also
illustrates the results of the induction therapy. Nine
patients (6 AML, 3 ALL) could not be included in
the study of the correlation of S-TK to remission
rate - 2 elderly men with AML who received no
cytostatic treatment and 7 patients (4 AML, 3
ALL) because of death from infection within 2
weeks after the start of therapy. Among the
patients evaluable in this respect, 13 with AML
failed to achieve complete remission and died of
therapy-resistant leukaemia. Their median
pretreatment S-TK value was 364unitspl-1, in
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contrast to 75units l-1 in the 35 patients with
AML who achieved complete remission. This
difference is highly significant (P<0.0001, Mann-
Whitney test). The AML patients in complete
remission were further analyzed concerning the
duration of remission. No correlation was found
between the pretreatment S-TK level and remission
duration using Cox's regression model (Cox et al.,
1972), but the follow-up time is not yet sufficient to
permit a firm conclusion. The patient with the
highest level (3050unitsyl-1) required 6 induction
courses before complete remission was achieved.
His remission lasted only 3 months. Only one of
the 9 evaluable ALL patients was resistant to
therapy and among the eight patients who achieved
complete remission two have relapsed.
Induction of remission in patients with acute
leukaemia demands hazardous treatment with
cytostatic combinations. In spite of very intensive
treatment, 20-30% of patients with AML and 10%
of patients with ALL still fail to achieve complete
remission (Lister et al., 1982). It is possible that this
group of patients may benefit from even more
aggressive induction therapy, although the risk of
therapy-related death may then increase
considerably. There are many reports on analyses
of correlations between the outcome of therapy and
pretreatment variables. The improved supportive
treatment has, however, made some of the
previously reported factors such as
thrombocytopenia, the presence of infectious
complications and advanced age less important.
With reduction in the failure of therapy due to
inadequate supportive care, more attention has
been focused on pretreatment variables that are
more likely to reflect the inherent nature of the
disease. Among these, chromosomal abnormalities
(Nilsson et al., 1977), a high serum lactic
dehydrogenase level (Keating et al., 1980) and the
presence of circulating immune complexes
(Carpentier et al., 1982) have been reported to
adversely affect the prognosis in AML. The FAB
classification of AML does not seem to be of
prognostic value (Gehan et al., 1976). There are
conflicting reports about the prognostic importance
of the blast cell count (Passe et al., 1982, Gehan et
al., 1976). In vitro growth characteristics of the
leukaemic bone marrow cells seem to correlate with
response to therapy (Spitzer et al., 1976). The
kinetics of the blast cell population has been
extensively investigated, using the thymidine
labeling index and flow cytofluorometric techniques
to"tneasure the proportion of cells synthesizing
DNA. Although a wide range of the percentage of
cells in the S phase has been found, results
concerning their prognostic value have been
conflicting (Crowther et al., 1975, Hart et al., 1977,
Dosik et al., 1980, Sewell et al., 1981). These
methods are especially interesting for the present
study, as TK is an enzyme with special preference
for cells undergoing transition from the dormant to
the dividing phase.
In this study we have shown that the
pretreatment level of S-TK is elevated in almost all
patients with acute leukaemia. Only 3/66 patients
had normal values. Enhanced activity of TK in
bone marrow has previously been found in patients
with acute leukaemia (Nakao & Fugihoka 1968).
Recently, elevated levels of S-TK were reported in
leukaemic mice and in a small number of patients
with acute leukaemia (Kreis et al., 1982). The cause
of the enhanced levels of S-TK in acute leukaemia
is not known. Widespread malignancies with a high
blast count such as small cell carcinoma of the lung
and non-Hodgkins lymphomas of unfavorable
histology are also associated with high levels of S-
TK (Gronowitz et al., 1983a). In vitamin B12
deficiency, a disorder with a proliferating
megaloblastic bone marrow with intramedullary
haemolysis, very high activities of TK both in the
bone marrow (Nakao et al., 1968) and in the serum
(Hagberg et al., 1984) have been found. Thus it is
possible that the high S-TK levels in acute
leukaemia mirror the release of TK from malignant
blasts cells. This release is probably dependent on
the intracellular concentration, the degree of blastic
destruction or leakage and the size of the tumor
mass. The level of S-TK may be a product of these
variables. In non-malignant leukocytosis or liver
damage, S-TK is not elevated, while some viral
disorders such as infectious mononucleosis give
transiently high levels (Gronowitz et al., 1984). We
have also found that the pretreatment level of S-TK
in AML correlates with the remission rate, with
higher values in patients with therapy-resistant
leukemia. The finding of S-TK as a prognostic
factor in AML further corroborates previous
observations in patients with non-Hodgkins
lymphoma (Ellims et al., 1981a,b,c; Gronowitz et
al., 1983), where S-TK correlates to stage and
histology, with higher values in more advanced
disease and more aggressive histology (Gronowitz
et al., 1983). In chronic lymphocytic leukaemia
(CLL) the S-TK level was found to be normal in
patients with indolent disease and elevated in most
of the patients with active disease (Kallander et al.,
1984). The elevation was, however, much lower
than in the patients with acute leukaemia. It is
difficult in this material to evaluate the importance
of S-TK as a prognostic factor in comparison with
other factors such as the level of peripheral blast
cell count and the lactic dehydrogenase. Although
this series of patients with acute leukaemia is too
small to permit a definite conclusion as to the
clinical usefulness of the S-TK assay, the results
seem promising and warrant further investigations.540 H. HAGBERG et al.
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